California Pacific Medical Center Research Institute, San Francisco, California 94107, USA.
J Biol Chem. 2011 Mar 4;286(9):7389-96. doi: 10.1074/jbc.M110.171454. Epub 2010 Dec 27.
ATP7B is a P-type ATPase involved in copper transport and homeostasis. In experiments with microsomes isolated from COS-1 cells or HepG2 hepatocytes sustaining ATP7B heterologous expression, we found that ATP7B utilization of ATP includes autophosphorylation of an aspartyl residue serving as ATPase catalytic intermediate as well as phosphorylation of serine residues by protein kinase D (PKD). The latter was abolished by specific PKD inhibition with CID755673. The presence of PKD protein in the microsomal fraction was demonstrated by Western blotting. PKD is a serine/threonine kinase that associates with the trans-Golgi network, regulating fission of transport carriers destined to the cell surface. Parallel studies on cultured cells showed that nascent WT ATP7B transits to the Golgi complex where it undergoes serine phosphorylation by PKD. Misfolded ATP7B protein (especially if subjected to deletions) underwent proteasome-mediated degradation, which provides effective quality control. Inhibition of proteasome-mediated degradation with MG132 yielded additional, but nonfunctional protein. On the other hand, serine phosphorylation protected WT ATP7B from degradation. Protection was enhanced by PKD activation with phorbol esters and limited by PKD inhibition with CID75673. As a final step, phosphorylated ATP7B was transferred from the Golgi complex to cytosolic trafficking vesicles. Phosphorylation and trafficking were completely prevented by mutations of critical copper binding sites, demonstrating copper dependence of both PKD-assisted phosphorylation and trafficking. ATP7B trafficking was markedly reduced by the Ser-478/481/1121/1453 to Ala mutation. We conclude that PKD plays a key role in copper-dependent serine phosphorylation, permitting high levels of ATP7B protein expression and trafficking.
ATP7B 是一种 P 型 ATP 酶,参与铜的运输和稳态。在使用从 COS-1 细胞或 HepG2 肝细胞分离的微粒体进行的实验中,我们发现 ATP7B 对 ATP 的利用包括天冬氨酸残基的自磷酸化,该残基作为 ATP 酶催化中间体,以及蛋白激酶 D (PKD) 对丝氨酸残基的磷酸化。后者被特异性 PKD 抑制剂 CID755673 所抑制。PKD 蛋白存在于微粒体部分,通过 Western 印迹证明。PKD 是一种丝氨酸/苏氨酸激酶,与高尔基网络相关联,调节运往细胞表面的运输载体的分裂。在培养细胞上进行的平行研究表明,新生 WT ATP7B 转运到高尔基复合物,在那里它被 PKD 进行丝氨酸磷酸化。错误折叠的 ATP7B 蛋白(特别是如果经历缺失)会经历蛋白酶体介导的降解,这提供了有效的质量控制。用 MG132 抑制蛋白酶体介导的降解会产生额外的,但无功能的蛋白质。另一方面,丝氨酸磷酸化保护 WT ATP7B 免受降解。PKD 激活剂佛波醇酯的激活增强了保护作用,而 CID75673 的 PKD 抑制则限制了保护作用。作为最后一步,磷酸化的 ATP7B 从高尔基复合物转移到胞质运输小泡。关键铜结合位点的突变完全阻止了磷酸化和运输,证明了 PKD 辅助磷酸化和运输对铜的依赖性。磷酸化和运输明显减少 Ser-478/481/1121/1453 到 Ala 突变。我们得出结论,PKD 在铜依赖性丝氨酸磷酸化中发挥关键作用,允许高水平的 ATP7B 蛋白表达和运输。